We tested B cell subsets isolated from HCs, RRMS patients before and after anti-CD20 therapy, and RRMS patients that were on natalizumab (anti-VLA4 integrin that binds to fibronectin/VCAM to cross the BBB) therapy. The gene discussed is FN1; the disease is relapsing-remitting multiple sclerosis.